Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker.

Zhang G, Zhang H, Wang Q, Lal P, Carroll AM, de la Llera-Moya M, Xu X, Greene MI.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):732-7. doi: 10.1073/pnas.0911397107. Epub 2009 Dec 18.

2.

A monoclonal antibody cytolytic to androgen independent DU145 and PC3 human prostatic carcinoma cells.

Talwar GP, Gupta R, Gupta SK, Malhotra R, Khanna R, Mitra DK, Sehgal S, Minz R, Kumar A.

Prostate. 2001 Feb 15;46(3):207-13.

PMID:
11170149
4.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
5.

Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).

Ling MT, Wang X, Lee DT, Tam PC, Tsao SW, Wong YC.

Carcinogenesis. 2004 Apr;25(4):517-25. Epub 2003 Dec 19.

PMID:
14688027
6.
7.
8.

Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.

Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A.

Cancer J. 2000 Jul-Aug;6(4):220-33.

PMID:
11038142
9.

TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.

Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ.

Clin Cancer Res. 2000 Mar;6(3):1190-7.

10.

Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.

Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A.

Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2658-63. Epub 2001 Feb 13.

11.
12.

Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.

Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):935-40. doi: 10.1016/j.ijrobp.2008.07.005. Epub 2008 Aug 28.

PMID:
18760546
13.

A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.

Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U.

Prostate. 2006 Sep 15;66(13):1359-70.

PMID:
16894535
14.

Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line.

Webber MM, Bello D, Kleinman HK, Wartinger DD, Williams DE, Rhim JS.

Carcinogenesis. 1996 Aug;17(8):1641-6.

PMID:
8761420
15.

Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.

Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.

Cancer J Sci Am. 1997 Jan-Feb;3(1):21-30.

PMID:
9072304
16.

Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.

Imai M, Ohta R, Varela JC, Song H, Tomlinson S.

Cancer Res. 2007 Oct 1;67(19):9535-41.

17.

Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.

Beckett ML, Lipford GB, Haley CL, Schellhammer PF, Wright GL Jr.

Cancer Res. 1991 Feb 15;51(4):1326-33.

18.

Rap2 regulates androgen sensitivity in human prostate cancer cells.

Bigler D, Gioeli D, Conaway MR, Weber MJ, Theodorescu D.

Prostate. 2007 Oct 1;67(14):1590-9.

PMID:
17918750
19.

A novel neoplastic primary tumor-derived human prostate epithelial cell line.

Ko D, Gu Y, Yasunaga Y, Nakamura K, Srivastava S, Moul JW, Sesterhenn IA, McLeod DG, Arnstein P, Taylor DO, Hukku B, Rhim JS.

Int J Oncol. 2003 Jun;22(6):1311-7.

PMID:
12738999
20.

Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.

Wolf P, Alt K, Bühler P, Katzenwadel A, Wetterauer U, Tacke M, Elsässer-Beile U.

Prostate. 2008 Feb 1;68(2):129-38.

PMID:
18044731

Supplemental Content

Support Center